Related references
Note: Only part of the references are listed.Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer et al.
LANCET (2021)
First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis
Ye Peng et al.
ADVANCES IN THERAPY (2021)
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy
Alessandro Di Federico et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H. Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
Tina R. Watson et al.
JAMA NETWORK OPEN (2020)
First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
Longfeng Zhang et al.
FRONTIERS IN ONCOLOGY (2020)
First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma A Cost-effectiveness Analysis
XiaoMin Wan et al.
JAMA ONCOLOGY (2019)
First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis
Ryul Kim et al.
CLINICAL LUNG CANCER (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Progress on drug pricing negotiations in China
Mi Tang et al.
BIOSCIENCE TRENDS (2019)
Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States
Steven D. Criss et al.
JAMA NETWORK OPEN (2019)
LUNG CANCER Frontline immunotherapy for NSCLC: alone or not alone?
Cesare Gridelli et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Value-Based Health Care Meets Cost-Effectiveness Analysis
Joel Tsevat et al.
ANNALS OF INTERNAL MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Alternative State-Level Financing for Hepatitis C Treatment-The Netflix Model
Mark R. Trusheim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Health state utilities in non-small cell lung cancer: An international study
Beenish Nafees et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
Julie R. Brahmer et al.
LANCET ONCOLOGY (2017)
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
Min Huang et al.
PHARMACOECONOMICS (2017)
The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable
Vinay Prasad et al.
MAYO CLINIC PROCEEDINGS (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs
Peter B. Bach et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer In what state is this art?
Keith M. Kerr et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs
Sham Mailankody et al.
JAMA ONCOLOGY (2015)
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
A. D'Incecco et al.
BRITISH JOURNAL OF CANCER (2015)
Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death
Anthony J. Hatswell et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2014)
Indication-Specific Pricing for Cancer Drugs
Peter B. Bach
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Comparative Effectiveness Questions in Oncology
Sham Mailankody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Updating Cost-Effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold
Peter J. Neumann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Update on Immune Checkpoint Inhibitors in Lung Cancer
Benjamin C. Creelan
CANCER CONTROL (2014)
Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource-Limited Setting
Bin Wu et al.
PLOS ONE (2012)
Revisiting Stage IIIB and IV Non-small Cell Lung Cancer Analysis of the Surveillance, Epidemiology, and End Results Data
William N. William et al.
CHEST (2009)
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Peter B. Bach
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Share Paper
